Another possible scenario is that Regimen 2 treated patients might present a higher population of breast cancer stem cells (BCSCs) identified by the cell-surface markers CD44+/CD24−/low which demonstrate chemo- and radiotherapy resistance [22-24]. Here, CD44 is linked to breast carcinoma.